Intestine and Lower Gastrointestinal Tract · 4 June 2024

Neoadjuvant Immunotherapy Safe for Rectal Cancer Surgery

Neoadjuvant immunotherapy for rectal cancer does not worsen surgical outcomes. A retrospective study of 26,229 patients showed no significant differences in length of stay, readmission, or mortality between those who received immunotherapy and those who did not. This suggests that adding immunotherapy to standard treatment protocols does not increase postoperative complications, offering clinicians valuable insights for optimizing patient-specific treatment strategies.

Journal Article by Shou M, Habib DRS (…) Khan A et 5 al. in J Surg Oncol

read the whole article in J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Dis Colon Rectum6 Nov 2026

Rectal Prolapse Emergencies Carry Worse Outcomes

Emergency admissions made up over a fifth of rectal prolapse hospital stays nationally, and those patients fared worse.

Dis Colon Rectum6 Nov 2026

Emergent Rectal Prolapse Admissions Carry Higher Risk

Nearly one in four rectal prolapse admissions in the US is emergent, and these patients fare worse.

Br J Surg5 Nov 2026

Rectal cancer and liver spread: similar outcomes

Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.

All papers in Intestine and Lower Gastrointestinal Tract →